ReviewFrontiers in immunology2026
Targeting regulated cell death pathways in lung cancer: mechanisms, therapeutic strategies, and clinical translation.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Association between prognostic nutritional index and prognosis in non-small cell lung cancer patients receiving PD-1/PD-L1 inhibitors: a meta-analysis.Frontiers in nutrition · 2026Pooled it
- CT-based deep learning for survival stratification in EGFR-mutant lung adenocarcinoma after EGFR-TKI resistance: A multicenter study.iScience · 2026Article
- Therapeutic Targeting of VEGFR-2, PD-L1, and EGFR-MET Pathways in Non-Small Cell Lung Cancer: Clinical Progress with Ramucirumab, Atezolizumab, and Amivantamab.Journal of clinical medicine · 2026Review
- Reactive oxygen species regulation of ferroptosis, autophagy, apoptosis, and immunogenic cell death in cancer.Frontiers in physiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung cancer is the leading cause of global cancer mortality, with treatment efficacy limited by high heterogeneity, drug resistance, and an immunosuppressive tumor microenvironment. Focusing primarily on non-small cell lung cancer (NSCLC), this review systematically analyzes eight key regulated cell death (RCD) pathways in lung cancer. These pathways are apoptosis, autophagy, necroptosis, ferroptosis, cuproptosis, pyroptosis, immunogenic cell death (ICD), and lysosome-dependent cell death (LDCD). Mechanistic dissection reveals complex crosstalk and a dynamic equilibrium among these pathways. For instance, apoptosis escape via EGFR/PI3K/Akt/mTOR signaling promotes survival, while autophagy exhibits a context-dependent dual role regulated by factors such as RBBP4 and the AURKA-CXCL5 axis. Importantly, several RCD pathways exert potent immunomodulatory functions. Necroptosis activates T cells by releasing damage-associated molecular patterns (DAMPs), while ferroptosis enhances NK cell cytotoxicity through GPX4 inactivation. Regarding therapeutic advances, synergistic strategies show promise, such as berberine with EGFR-TKIs inducing apoptosis via EGFR degradation, and (-)-Guaiol triggering ICD to synergize with PD-1/PD-L1 inhibitors. Novel inducers, including Auranofin (ferroptosis), TMEM100 agonists (necroptosis), and cuproptosis nanomedicines (e.g., DE-Cu
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.